# Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

> **NCT00354367** · PHASE3 · WITHDRAWN · sponsor: **UCB Pharma**

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Certolizumab pegol

## Key facts

- **NCT ID:** NCT00354367
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354367, "Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00354367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*